We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$239M
Cap. Flow %
-32.31%
Top 10 Hldgs %
67%
Holding
218
New
56
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Healthcare 6.89%
2 Financials 5.45%
3 Technology 3.65%
4 Industrials 1.84%
5 Communication Services 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
101
Amarin Corp
AMRN
$293M
$759K 0.1%
7,439
-8,910
-54% -$875K
ATOS icon
102
CALL
Atossa Therapeutics
ATOS
$24.1M
$713K 0.1%
146
+45
+45% +$2.62K
OPTT icon
103
PUT
Ocean Power Technologies
OPTT
$40.6M
$703K 0.1%
3,029
-1,151
-28% -$2.41K
LEXXW
104
DELISTED
Lexaria Bioscience Warrant
LEXXW
$699K 0.09%
332,971
-68,275
-17% -$168K
RKDA icon
105
PUT
Arcadia Biosciences
RKDA
$1.37M
$684K 0.09%
83
-126
-60% -$11.8K
VANI icon
106
PUT
Vivani Medical
VANI
$113M
$680K 0.09%
+711
New +$8.01K
DXR icon
107
Daxor
DXR
$62.2M
$677K 0.09%
57,924
-39,563
-41% -$403K
CFRX
108
DELISTED
ContraFect Corporation
CFRX
$673K 0.09%
2,077
– –
CTRM icon
109
Castor Maritime
CTRM
$18.3M
$666K 0.09%
27,313
+17,960
+192% +$403K
CTRM icon
110
PUT
Castor Maritime
CTRM
$18.3M
$637K 0.09%
261
+188
+258% +$4.22K
BNKK
111
Bonk Inc
BNKK
$8.32M
$582K 0.08%
+11,798
New +$930K
BKYI
112
PUT
BIO-key International
BKYI
$4.61M
$571K 0.08%
9
– –
NCTY
113
The9 Ltd
NCTY
$70.6M
$543K 0.07%
5,269
+1,579
+43% +$199K
LNAI
114
Lunai Bioworks
LNAI
$10.2M
$534K 0.07%
991
-15,780
-94% -$7.71M
KDMN
115
DELISTED
Kadmon Holdings, Inc.
KDMN
$526K 0.07%
+60,351
New +$344K
NMTR
116
CALL
DELISTED
9 Meters Biopharma
NMTR
$475K 0.06%
183
+140
+326% +$3.3K
AMPGW
117
DELISTED
Amplitech Group Warrants
AMPGW
$453K 0.06%
348,673
+11,074
+3% +$15.9K
STKH
118
Steakholder Foods
STKH
$2.13M
$443K 0.06%
61
+8
+15% +$60.3K
XBI icon
119
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$440K 0.06%
+3,500
New +$451K
GYRE icon
120
Gyre Therapeutics
GYRE
$668M
$435K 0.06%
+14,099
New +$464K
PDSB icon
121
PUT
PDS Biotechnology
PDSB
$38.6M
$423K 0.06%
+284
New +$3.54K
ZVRA icon
122
Zevra Therapeutics
ZVRA
$575M
$387K 0.05%
41,531
-130,632
-76% -$1.32M
GLBS icon
123
PUT
Globus Maritime Ltd
GLBS
$60.9M
$368K 0.05%
1,259
-140
-10% -$426
EQOS
124
DELISTED
EQONEX LIMITED Ordinary Shares
EQOS
$365K 0.05%
+112,533
New +$571K
ADTX
125
PUT
DELISTED
ADITXT INC
ADTX
– –
0
– –
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $239M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.9% of assets, down from 10% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 56 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.